Drug development for stroke: Importance of protecting cerebral white matter

European Journal of Pharmacology

Volumn 375, Issue 1-3, 1999, Pages 41-50

  Dewar, Deborah ^a   Yam, Philippa ^a   McCulloch, James ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Axon; Cerebral ischemia; Oligodendrocyte; Stroke

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ADENOSINE; AMPA RECEPTOR ANTAGONIST; DIZOCILPINE;

ANIMAL EXPERIMENT; BRAIN ISCHEMIA; BRAIN PROTECTION; CAT; CONTROLLED STUDY; DRUG DEVELOPMENT; NERVE FIBER; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RAT; REVIEW; STROKE; WHITE MATTER;

ANIMALS; AXONS; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; HUMANS; OLIGODENDROGLIA; TECHNOLOGY, PHARMACEUTICAL;

EID: 0033053635     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00280-0     Document Type: Review

References (67)

1. Back S.A., Gan X., Li Y., Rosenberg P.A., Volpe J.J. Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion. J. Neurosci. 18:1998;6241-6253.
2. Baird A.E., Warach S. Magnetic resonance imaging of acute stroke. J. Cereb. Blood Flow Metab. 18:1998;583-609.
3. Bartus R.T., Baker K.L., Heiser A.D., Sawyer S.D., Dean R.L., Elliott P.J., Straub J.A. Post-ischaemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain-damage. J. Cereb. Blood Flow Metab. 14:1994;537-544.
4. Bartus R.T., Hayward M.J., Elliott P.J., Sawyer S.D., Baker K.L., Dean R.L., Akiyama A., Straub J.A., Harbeson S.L., Li Z., Powers J. Calpain inhibitor AK295 protects neurons from focal brain ischemia - effects of postocclusion intraarterial administration. Stroke. 25:1994;2265.
5. Bartus R.T., Dean R.L., Cavanaugh K., Eveleth D., Carriero D.L., Lynch G. Time-related neuronal changes following middle cerebral artery occlusion - implications for therapeutic intervention and the role of calpain. J. Cereb. Blood Flow Metab. 15:1995;969-979.
6. Cao X., Phillis J.W. A-Phenyl-tert-butyl-nitrone reduces cortical infarct and edema in rats subjected to focal ischemia. Brain Res. 644:1994;267-272.
7. Compston, A., 1993. Non-infective inflammatory, demyelinating, and paraneoplastic diseases of the nervous system. In: Walton, J. (Ed.), Brain's Diseases of the Nervous System. Oxford Univ. Press, pp. 351-358.
8. Dewar D., Dawson D. Tau protein is altered by focal cerebral ischaemia in the rat: an immunohistochemical and immunoblotting study. Brain Res. 684:1995;70-78.
9. Dewar D., Dawson D. Changes of cytoskeletal protein immunostaining in myelinated fibre tracts after focal cerebral ischaemia in the rat. Acta Neuropathol. 93:1996;71-77.
10. Dewar D., Yam P., Dunn L., McCulloch J. Oligodendrocyte pathology and its relation to axonal APP accumulation in white matter after focal cerebral ischaemia in the cat. J. Cereb. Blood Flow Metab. 19:1999;S665. Suppl.
11. Dietrich W.D., Kraydieh S., Prado R., Stagliano N.E. White matter alterations following thromboembolic stroke: a β-amyloid precursor protein immunocytochemical study in rats. Acta Neuropathol. 95:1998;524-531.
12. Du C., Hu R., Csernansky C.A., Hsu C.Y., Choi D.W. Very delayed infarction after middle focal cerebral ischaemia: a role for apoptosis? J. Cereb. Blood Flow Metab. 16:1996;195-201.
13. Dyker A.G., Lees K.R. Duration of neuroprotective treatment for ischemic stroke. Stroke. 29:1998;535-542.
14. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain. 120:1997;393-399.
15. Fern R., Waxman S.G., Ransom B.R. Modulation of anoxic injury in CNS white-matter by adenosine and interaction between adenosine and GABA. J. Neurophys. 6:1994;2609-2616.
16. Fern R., Waxman S.G., Ransom B.R. Endogenous GABA attenuates CNS white-matter dysfunction following anoxia. J. Neurosci. 15:1995;699-708.
17. Folbergrova J., Zhao Q., Katsura K.-I., Siesjö B.P. N-tert-Butyl-α-phenylnitrone improves recovery of brain energy state in rats following transient focal ischaemia. Proc. Natl. Acad. Sci. USA. 92:1995;5057-5061.
18. Garcia-Barcina J.M., Matute C. Expression of kainate-selective glutamate receptor subunits in glial cells of the adult bovine white matter. Eur. J. Neurosci. 8:1996;2379-2387.
19. Graham D.I., Ford I., Adams J.H., Doyle D., Teasdale G.M., Lawrence A.E., McLellan D.R. Ischaemic brain damage is still common in fatal non-missile head injury. J. Neurol. Neurosurg. Psychiatry. 52:1989;346-350.
20. Griffiths I., Klugmann M., Anderson T., Yool D., Thomson C., Schwab M.H., Schneider A., Zimmerman F., McCulloch M., Nadon N., Nave K.-A. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science. 280:1998;1610-1613.
21. Hong S.C., Goto Y., Lanzino G., Soleau S., Kassell N.F., Lee K.S. Neuroprotection with a calpain inhibitor in a model of focal cerebral-ischemia. Stroke. 25:1994;663-669.
22. Hunter A.J., Mackay K.B., Rogers D.C. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? TiPS. 19:1998;59-66.
23. 2+-dependent injury of the dorsal columns. J. Neurotrauma. 14:1997;299-311.
24. Irving E.A., Nicoll J., Graham D.I., Dewar D. Increased tau immunoreactivity in oligodendrocytes following human stroke and head injury. Neurosci. Lett. 213:1996;189-192.
25. Irving E.A., Yatsushiro K., McCulloch J., Dewar D. Rapid alteration of tau in oligodendrocytes after focal ischemic injury in the rat: involvement of free radicals. J. Cereb. Blood Flow Metab. 17:1997;612-622.
26. Jones T.J., Morawetz R.B., Crowell R.M., Marcoux F.W., Fitzgibbon S.J., Degirolami U., Ojemann R.G. Thresholds of focal cerebral ischemia in awake monkeys. J. Neurosurg. 54:1981;773-782.
27. Kim Y.S., Kim S.U. Oligodendroglial cell death induced by oxygen radicals and its protection by catalase. J. Neurosci. Res. 29:1991;100-106.
28. Koroshetz W.J., Moskowitz M.A. Emerging treatments for stroke in humans. TiPS. 17:1996;227-233.
29. Laskiewicz I., Mouzannar R., Wiggins R.C., Konat G.W. Delayed oligodendrocyte degeneration induced by brief exposure to hydrogen peroxide. J. Neurosci. Res. 55:1999;303-310.
30. Markgraf C.G., Velayo N.L., Johnson M.P., McCarty D.R., Medhi S., Koehl J.R., Chmielewski P.A., Linnik M.D. Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke. 29:1998;152-158.
31. Matute C., Sánchez-Gómez M.V., Martínez-Millán L., Miledi R. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc. Natl. Acad. Sci. USA. 94:1997;8830-8835.
32. McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man. Br. J. Clin. Pharmacol. 34:1992;106-114.
33. McCulloch, J., Bullock, R., Teasdale, G.M., 1991. Excitatory amino acid antagonists: opportunities for the treatment of ischaemic brain damage in man. In: Meldrum, B.S. (Ed.), Excitatory Amino Acid Antagonists. Blackwell/Oxford, pp. 287-326.
34. McDonald J.W., Althomsons S.P., Hyrc K.L., Choi D.W., Goldberg M.P. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat. Med. 4:1998;291-297.
35. Mies G., Ishimaru S., Xie Y., Seo K., Hossmann K.-A. Ischemic thresholds of cerebral protein synthesis and energy state following middle cerebral artery occlusion in rat. J. Cereb. Blood Flow Metab. 11:1991;753-761.
36. Mitrovic B., Ignarro L.J., Montestruque S., Smoll A., Merrill J.E. Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro. Neuroscience. 61:1994;575-585.
37. Mitrovic B., Ignarro L.J., Vinters J.V., Akers M.-A., Schmid I., Uittenbogaart C., Merrill J.E. Nitric oxide induces necrotic but not apoptotic cell death in oligodendrocytes. Neuroscience. 65:1995;531-539.
38. A receptor activation attenuates excitotoxicity but exacerbates oxygen-glucose deprivation-induced neuronal injury in vitro. J. Cereb. Blood Flow Metab. 16:1996;1211-1218.
39. Oka A., Belliveau M.J., Rosenberg P.A., Volpe J.J. Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms and prevention. J. Neurosci. 13:1993;1441-1453.
40. Osborne K.A., Shigeno T., Balarsky A.M., Ford I., McCulloch J., Teasdale G.M., Graham D.I. Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia. J. Neurol. Neurosurg. Psychiatry. 50:1987;402-410.
41. Ozyurt E., Graham D.I., Woodruff G.N., McCulloch J. Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia in the cat. J. Cereb. Blood Flow Metab. 8:1988;138-143.
42. Pantoni L., Garcia J.H., Gutierrez J.A. Cerebral white matter is highly vulnerable to ischemia. Stroke. 27:1996;1641-1647.
43. Park C.K., Nehls D.G., Graham D.I., Teasdale G.M., McCulloch J. Focal cerebral ischaemia in the cat: treatment with the glutamate antagonist MK-801 after induction of ischaemia. J. Cereb. Blood Flow Metab. 8:1988;757-762.
44. Patneau D.K., Wright P.W., Winters C., Mayer M.L., Gallo V. Glial cells of the oligodendrocyte lineage express both kainate- and AMPA-preferring subtypes of glutamate receptor. Neuron. 12:1994;357-371.
45. Petito C.K. Transformation of post-ischemic perineuronal glial cells: I. Electron microscopic studies. J. Cereb. Blood Flow Metab. 6:1986;616-624.
46. Richter-Lansberg C., Vollgraf U. Mode of cell injury and death after hydrogen peroxide exposure in cultured oligodendroglia cells. Exp. Cell Res. 244:1998;218-229.
47. Rosenberg L.J., Teng Y.D., Wrathall J.R. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline reduces glial loss and acute white matter pathology after experimental spinal cord contusion. J. Neurosci. 19:1999;464-475.
48. Rudolphi K.A., Schubert P., Parkinson F.E., Fredholm B.B. Neuroprotective role of adenosine in cerebral ischaemia. TiPS. 13:1992;439-445.
49. Siesjö, B.K., Katsura, K., Pahlmark, K., Smith, M.-L., 1992. In: Krieglstein, J., Oberpichler-Schwenk, H. (Eds.), The Multiple Causes of Ischemic Brain Damage: A Speculative Synthesis. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
50. Stephenson D.T., Rash K., Clemens J.A. Amyloid precursor protein accumulates in regions of neurodegeneration following focal cerebral ischemia in the rat. Brain Res. 393:1992;128-135.
51. Sternau L.L., Lust W.D., Ricci A.J., Ratcheson R. Role for γ-aminobutyric acid in selective vulnerability in gerbils. Stroke. 20:1989;281-287.
52. Stys P.K. Anoxic and Ischemic injury of myelinated axons in CNS white matter: from mechanistic concepts to therapeutics. J. Cereb. Blood Flow Metab. 18:1998;2-25.
53. Stys P.K., Lesiuk H. Correlation between electrophysiological effects of mexiletine and ischemic protection in central nervous system white matter. Neuroscience. 71:1996;27-36.
54. Stys P.K., Ransom B.R., Waxman S.G. Effects of polyvalent cations and dihydropyridine calcium channel blockers on recovery of CNS white matter from anoxia. Neurosci. Lett. 115:1990;293-299.
55. Tamura A., Graham D.I., McCulloch J., Teasdale G.M. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 1:1981;53-60.
56. 14C ]iodoantipyrine autoradiography following middle cerebral artery occlusion J. Cereb. Blood Flow Metab. 1:1981;61-69.
57. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333:1995;1581-1587.
58. Touzani O., Galbraith S., Siegl P., McCulloch J. Endothelin-B receptors in cerebral resistance arterioles and their functional significance after focal cerebral ischemia in cats. J. Cereb. Blood Flow Metab. 17:1997;1157-1165.
59. Tyson G.W., Teasdale G.M., Graham D.I., McCulloch J. Cerebrovascular permeability following middle cerebral artery occlusion in the rat: the effect of halothane induced hypotension. J. Neurosurg. 57:1982;186-196.
60. Tyson G., Teasdale G.M., Graham D.I., McCulloch J. Focal cerebral ischemia in the rat: topography of hemodynamic and histopathological changes. Ann. Neurol. 15:1984;559-567.
61. Waxman S.G., Black J.A., Stys P.K., Ransom B.R. Ultrastructural concomitants of anoxic injury and early post-anoxic recovery in rat optic nerve. Brain Res. 574:1992;105-119.
62. Waxman S.G., Black J.A., Ransom B.R., Stys P.K. Protection of the axonal cytoskeleton in anoxic optic nerve by decreased extracellular calcium. Brain Res. 614:1993;137-145.
63. Yam P.S., Takasago T., Dewar D., Graham D.I., McCulloch J. Amyloid precursor protein accumulates in white matter at the margin of a focal ischaemic lesion. Brain Res. 760:1997;150-157.
64. Yam P.S., Dewar D., McCulloch J. Axonal injury caused by focal cerebral ischemia in the rat. J. Neurotrauma. 15:1998;441-450.
65. Yam P.S., Dunn L., Graham D.I., McCulloch J. Quantitative analysis of axonal injury following focal cerebral ischaemia in the cat: the effect of MK-801 administration. J. Cereb. Blood Flow Metab. 19:1999;S146. Suppl.
66. Yoshioka A., Hardy M., Younkin D.P., Grinspan J.B., Stern J.L., Pleasure D. α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors mediate excitotoxicity in the oligodendroglial lineage. J. Neurochem. 64:1995;2442-2448.
67. Zea Longa E., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:1989;84-91.